{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:57:21Z","timestamp":1791244641853,"version":"4.1.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T00:00:00Z","timestamp":1547596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objective:<\/jats:title>\n                    <jats:p>Disseminated BCGitis is a rare but serious complication of BCG vaccine in patients with underlying primary immunodeficiency. Fluoroquinolone antibiotics containing antimycobacterial regimen have been considered in the treatment of disseminated BCGitis, but there are limited data about the dosing, safety, and tolerability of fluoroquinolone such as moxifloxacin in children. The aim of this study was to report the experience with the dosing, safety, and tolerability of moxi- floxacin in children with disseminated BCGitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>This retrospective descriptive study included children who had been diagnosed with disseminated BCGitis and treated with an antimycobacterial regimen including moxifloxacin for more than two weeks from 2007 to 2017 at King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result:<\/jats:title>\n                    <jats:p>Ten children were included: six (60.0%) were male and four (40.0%) were female. The primary diagnosis for five patients was Mendelian susceptibility to mycobacterial diseases (MSMD), four patients were diagnosed with severe combined immune deficiency (SCID), and the remaining patient had human immunodeficiency virus (HIV) infection. The overall mean duration of moxifloxacin treatment was 10.1 months. Liver toxicity was recorded in three patients. The most common medications used with mox- ifloxacin were ethambutol and clarithromycin. Moxifloxacin serum concentration level was determined in 5 patients. No musculoskeletal side effects were reported while the patient was on moxifloxacin. The treated patients showed a different response to an antimycobacterial regimen including moxifloxacin, with mortality in two patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our study suggests that moxifloxacin is generally tolerated in children and might be considered in disseminated BCGitis cases. Additionally, paying attention to side effects such as liver toxicity is recommended, particularly with the use of other antimycobacterial antibiotics, which could also be hepatotoxic. A moxifloxacin-containing regimen for disseminated BCGitis showed clinical improvement in some patients in this study, although the majority presented the same clinical condition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.ijpam.2019.01.003","type":"journal-article","created":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T17:00:57Z","timestamp":1547917257000},"page":"47-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety and tolerability of moxifloxacin for the treatment of disseminated BCGitis in children"],"prefix":"10.4103","volume":"6","author":[{"given":"Mohammed","family":"Alsuhaibani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada","family":"Felimban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Shoukri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Alosaimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Almohaizeie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"AlHajjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20240319","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1086\/499953","article-title":"Bacille Calmette-Gu\u00e9rin vaccine\u2013induced disease in HIV-infected and HIV- uninfected children","volume":"42","author":"Hesseling","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R2-2-20240319","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijpam.2015.05.003","article-title":"Bacillus calmette\u2013gu\u00e9rin vaccine related lymphadenitis in children: management guidelines endorsed by the Saudi pediatric infectious diseases society (SPIDS)","volume":"2","author":"Elsidig","year":"2015","journal-title":"Int J Pediatr Adolesc Med"},{"key":"R4-2-20240319","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5144\/0256-4947.2012.1","article-title":"Bacille calmette\u2013guerin vaccination in Saudi Arabia: benefits versus risks","volume":"32","author":"Al Jumaah","year":"2012","journal-title":"Ann Saudi Med"},{"key":"R5-2-20240319","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4103\/1817-1737.114303","article-title":"Tuberculosis incidence trends in Saudi Arabia over 20 years: 1991-2010","volume":"8","author":"Al-Orainey","year":"2013","journal-title":"Ann Thorac Med"},{"key":"R6-2-20240319","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1128\/AAC.01302-08","article-title":"Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics","volume":"53","author":"Ritz","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R7-2-20240319","doi-asserted-by":"crossref","first-page":"512","DOI":"10.5144\/0256-4947.1996.512","article-title":"Clinical features and outcome of eleven patients with disseminated bacille Calmette- Guerin (BCG) infection","volume":"16","author":"Al Arishi","year":"1996","journal-title":"Ann Saudi Med"},{"key":"R8-2-20240319","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1542\/peds.98.4.774","article-title":"Idiopathic disseminated bacillus Calmette-Guerin infection: a French national retrospective study","volume":"98","author":"Casanova","year":"1996","journal-title":"Pediatrics"},{"key":"R9-2-20240319","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.tube.2015.02.037","article-title":"Fluoroquinolones for the treatment of tuberculosis in children","volume":"95","author":"Thee","year":"2015","journal-title":"Tuberculosis"},{"key":"R10-2-20240319","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/ppul.22755","article-title":"Moxifloxacin for the treatment of pulmonary tuberculosis in children: a single center experience","volume":"49","author":"Garazzino","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"R11-2-20240319","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/cid\/ciu868","article-title":"Pharmacokinetics and safety of moxifloxacin in children with multidrug- resistant tuberculosis","volume":"60","author":"Thee","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R12-2-20240319","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1093\/cid\/ciw483","article-title":"Optimal clinical doses of faropenem, linezolid, and moxifloxacin in children with disseminated tuberculosis: Goldilocks","volume":"63","author":"Srivastava","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R13-2-20240319","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/jcph.968","article-title":"A review of moxi- floxacin for the treatment of drug-susceptible tuberculosis","volume":"57","author":"Naidoo","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"R14-2-20240319","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1086\/521894","article-title":"Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis","volume":"45","author":"Nijland","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R15-2-20240319","first-page":"3696","article-title":"Disseminated Bacille Calmette\u2013Gu\u00e9rin disease in Saudi children: clinical profile, microbiology, immunology evaluation and outcome","volume":"20","author":"Bukhari","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R16-2-20240319","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijpam.2014.11.005","article-title":"An infant with disseminated bacillus Calmette-Guerin infection (BCGitis)","volume":"1","author":"Al-Mousa","year":"2014","journal-title":"Int J Pediatr Adolesc Med"},{"key":"R17-2-20240319","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.5588\/ijtld.12.0042","article-title":"In vitro susceptibility of Mycobacterium bovis against moxifloxacin","volume":"16","author":"Weiss","year":"2012","journal-title":"Int J Tubercul Lung Dis"},{"key":"R18-2-20240319","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJMoa0800106","article-title":"Comprehensive treatment of extensively drug-resistant tuberculosis","volume":"359","author":"Mitnick","year":"2008","journal-title":"N Engl J Med"},{"key":"R19-2-20240319","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.tube.2011.11.001","article-title":"Paediatric use of second-line anti-tuberculosis agents: a review","volume":"92","author":"Seddon","year":"2012","journal-title":"Tuberculosis"},{"key":"R20-2-20240319","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.rmed.2006.01.002","article-title":"Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs","volume":"100","author":"Codecasa","year":"2006","journal-title":"Respir Med"},{"key":"R21-2-20240319","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1093\/jpids\/piy056","article-title":"Safety and tolerability of moxifloxacin in children","volume":"7","author":"Dixit","year":"2018","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R22-2-20240319","doi-asserted-by":"crossref","first-page":"e1253","DOI":"10.1542\/peds.2009-2172","article-title":"Two pediatric cases of multidrug-resistant tuberculosis treated with linezolid and moxifloxacin","volume":"126","author":"Pinon","year":"2010","journal-title":"Pediatrics"}],"container-title":["International Journal of Pediatrics and Adolescent Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352646718301996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352646718301996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/01863514-201906020-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:28:15Z","timestamp":1786735695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01863514-201906020-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ijpam.2019.01.003","relation":{},"ISSN":["2352-6467"],"issn-type":[{"value":"2352-6467","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and tolerability of moxifloxacin for the treatment of disseminated BCGitis in children","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pediatrics and Adolescent Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpam.2019.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Publishing services provided by Elsevier B.V. on behalf of King Faisal Specialist Hospital & Research Centre (General Organization), Saudi Arabia.","name":"copyright","label":"Copyright"}]}}